Page 3 - Booklet "BIH Strategy 2026"

Prof Erwin Böttinger
Chief Executive O icer
WELCOME
Dr Rolf Zettl
Chief Financial O icer
Prof Karl Max Einhäupl
Charité – Universitäts­ medizin Berlin Chief Executive O icer
Prof Axel Radlach Pries
Charité – Universitäts­ medizin Berlin Dean
Prof Martin Lohse
Max Delbrück Center for Molecular Medicine in in the Helmholtz Association Chair of MDC Board
The developed and developing worlds alike are increas­ ingly burdened by noncommunicable diseases Illnesses such as as heart disease cancer and dementia have a a a a a a a a huge impact on
our societies causing untenable morbid­ ities and and mortality With people now living longer and and expecting better health and quality of life in in old age a a a a a new approach is needed We believe the emerging elds of personalized medi­ cine and new advanced therapies o o er er a a a a a a promising way forward Since the year 2000 great strides have been made in in biomedical research not least the unraveling
of the human genome advances in stem cells and cell­based therapies and new prospects for gene therapy through genome editing technologies Coupled with advances in in in digital medicine and information sciences these innovative elds have created huge opportunities to develop new ways of tackling in in particular progres­ sive forms of noncommunicable disease The Berlin Institute of Health aims to create an innova­ tive translational research commons of Charité – Univer­ sitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine in in the Helmholtz Association (MDC) The BIH Research Commons is enhancing personalized medicine and advanced therapies research in in Germany
and aims to to develop predictive tools for personalized medicine as as well as as advanced therapies that save lives and prolong quality of of life It is not the rst of of its kind but we want to make it among the best The new Board
is now leading BIH into an exciting phase Our job is to to build on
on
solid foundational work to to grow the institute and meet the objectives laid out in in our ten­year BIH Strategy 2026 which this booklet communicates We are ambitious In just a a a a a a few years we want to have recruited the brightest and most ambitious faculty
and sta created multiple research initiatives covering emerging areas from digital medicine to cell engineering and perhaps even have already developed new diagnos­ tics or therapies And by 2026 we will have established
a a a robust ecosystem where innovation
is a a a driving force for for better health and quality of life Our approach will always be integrated forward thinking and research driven: our aim always to make the best possible use of life and data sciences for personalized medicine and advanced therapies Welcome to future medicine The Executive Board
of of the Berlin Institute of of Health Maintaining Health and Quality of Life Creating Value: BIH Strategy 2026 3